Recruiting PHASE2/PHASE3 INTERVENTIONAL 3-arm
NCT06855095
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial (ATSA)
Sponsor: Neuroendocrine Tumor Research Foundation
Conditions
Neuroendocrine Neoplasm Neuroendocrine Tumor Grade 1 Neuroendocrine Tumor Grade 2 Neuroendocrine Tumors
Interventions
Somatostatin analog
Updated 1 time since 2025 Last updated: Feb 26, 2025 Started: Jun 25, 2024 Primary completion: Jan 1, 2027 Completion: Mar 1, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06855095, this PHASE2/PHASE3 trial focuses on Neuroendocrine Neoplasm and Neuroendocrine Tumor Grade 1 and remains actively recruiting participants. Sponsored by Neuroendocrine Tumor Research Foundation, it has been updated 1 time since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Recruiting — PHASE2/PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Neuroendocrine Tumor Research Foundation
- The Netherlands Cancer Institute
Data source: The Netherlands Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .